Bovine Mastitis Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Bovine Mastitis Market Trends and Insights

Rising Incidence and Cost Burden

Mastitis affects one in four U.S. dairy cows each year, with every clinical case costing from USD 128 to USD 444 in lost milk, treatment, and culling expenses^{[1]Thermo Fisher Scientific, “Bovine Diagnostics: How Much Does Mastitis Cost Dairy Producers Annually,” thedairysite.com}. Subclinical infections silently depress yield by 10% to 20% per cow, prompting European herds to adopt routine somatic-cell screening to avoid milk-quality penalties. The mounting financial toll steers producer budgets toward predictive analytics, vaccination programs, and selective therapy, which all underpin sustained demand in the bovine mastitis market.

Growth in Veterinary Spending and Herd-Management Automation

Large farms are allocating bigger capital outlays to automated milking systems, inline sensors, and professional veterinary services. DeLaval and John Deere’s Milk Sustainability Center illustrates how cloud-based dashboards now merge feed, fertility, and udder-health data to boost profitability. Asia-Pacific herds are scaling rapidly, replicating Western automation models and lifting regional sales of diagnostics, vaccines, and decision-support software that keep the bovine mastitis market expanding at the fastest clip worldwide.

Technological Advances in On-Farm Diagnostics and Sensors

AI-enabled image analysis and IoT milk-conductivity probes detect Gram-positive pathogens in hours rather than days. Zoetis’ Vetscan Mastigram+ identifies Gram-positive mastitis within 8 hours, cutting blanket antibiotic use. Trial data show machine-learning models reach over 95% accuracy for subclinical detection^{[2]Moonsun Shin, “AI-Based Smart Monitoring Framework for Livestock Farms,” Applied Sciences, mdpi.com} , though farms still face false-positive alerts that vendors are tackling through refined algorithms.

Adoption of Short-Withdrawal Intramammary Antibiotics

Regulators now favor products that preserve milk sales. The FDA approval of Flunine and Merck’s BANAMINE TRANSDERMAL set the tone for 48-hour milk-withdrawal therapies. EU rules mandating selective dry-cow therapy spur R&D into formulations that balance potency with minimal residue, reinforcing demand in the bovine mastitis market.

Escalating Antimicrobial Resistance (AMR)

EU Regulation 2019/6 has banned prophylactic use and tightened metaphylactic approvals^{[3]Ivo Schmerold, “European regulations on the use of antibiotics in veterinary medicine,” European Journal of Pharmaceutical Sciences, sciencedirect.com}, forcing practitioners to blend systemic and intramammary drugs with NSAIDs to manage resistant strains. MRSA outbreaks in cattle shrink cure rates and elevate costs, dampening short-term growth until vaccines and phage solutions mature.

Low Farmer Adherence in Emerging Markets

Studies in Brazil and Rwanda show gaps between veterinary guidance and on-farm practice, owing to cost constraints and limited extension services. Pilot One-Health projects^{[4]Sara N Garcia, “A one health framework to advance food safety and security: An on-farm case study in the Rwandan dairy sector,” PubMed, pubmed.ncbi.nlm.nih.gov} lift compliance to 90% when training is provided, yet scaling such programs remains a hurdle that restrains the bovine mastitis industry in developing regions.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Disease Type: Clinical Cases Drive Treatment Urgency

Clinical mastitis held 58.02% of the bovine mastitis market size in 2025 and is expanding at 5.18% CAGR on the back of visible symptoms that demand immediate treatment to avoid milk loss and animal welfare penalties. Rapid therapy translates to higher spending per case, sustaining revenue streams for antibiotics and NSAIDs. The economic sting of each clinical outbreak keeps producers alert to early warning sensors that flag udder swelling or milk discoloration.

Subclinical infections trail in market value yet contribute 10%-20% latent yield loss, prompting investment in somatic-cell count trackers and AI pattern recognition. Smartphones now deliver 2-minute cell-count reads, nudging farms toward proactive cures that could soon narrow the revenue gap with clinical cases. As technology shrinks diagnostic costs, the subclinical sub-segment may accelerate faster than headline projections, adding depth to the bovine mastitis market.

By Product: Antibiotic Dominance Faces Innovation Pressure

Antibiotics accounted for 76.62% of the bovine mastitis market share in 2025 and are on track to grow at a good pace through 2031. Their dominance stems from fast, reliable cures in acute clinical cases, which protect both cow welfare and farm income. Regulators are tightening oversight; however, the European Union now restricts prophylactic use and scrutinizes critical drug classes, prompting more selective prescribing.

Vaccines are the quickest-rising category, advancing at a 5.62% CAGR, as prevention proves cheaper than treatment and supports industry efforts to curb antibiotic reliance. Zoetis’ Protivity for Mycoplasma bovis and other multi-pathogen projects show the pivot toward immunological control.

By Route of Administration: Systemic Delivery Maintains Dominance

Systemic therapies made up 86.10% of the bovine mastitis market size in 2025 and are set to climb at 5.05% CAGR because they address both localized and systemic infections while simplifying dosing. Injectable ceftiofur or oral formulations save labor in large herds where time per cow is at a premium.

Intramammary products, though smaller in value, allow high local drug concentrations and reduced residues. The FDA’s 21 CFR Part 526 pathway guides new extended-release tubes that maintain therapy across the dry period without repeated infusions. As more selective dry-cow programs roll out, intramammary lines may edge up their contribution to overall bovine mastitis market growth.

By Therapy: Dry-Period Treatment Leads Prevention Focus

Dry-period therapy captured 62.04% of the bovine mastitis market share in 2025 and posts the fastest CAGR at 5.36%. Treating cows between lactations sidesteps withdrawal losses and lets antibiotics linger for complete pathogen clearance. EU mandates now require culture-based selection, spurring diagnostics that decide which quarters need dosing and which can transition to internal teat sealants alone.

Lactation-period therapy grapples with milk-discard costs and AMR rules but benefits from recent approvals that cut withholding intervals to 48 hours. Anti-inflammatory combinations shorten clinical signs and help producers keep mastitis-affected cows in production. Both dynamics preserve demand across the bovine mastitis market as farms balance productivity with compliance.

By End-User: Dairy Farms Drive Direct Implementation

Dairy farms and cooperatives accounted for 79.55% of the bovine mastitis market size in 2025 and advance at 5.11% CAGR because they shoulder the direct economic burden of mastitis. Consolidating herds wield procurement power, purchasing diagnostics and therapeutics in bulk and integrating them into digital farm-management suites.

Veterinary hospitals remain central for complex or chronic cases that need culture, sensitivity testing, or surgery. Zoetis’ Louisville reference lab extension offers faster microbial identification, underscoring the link between lab capacity and frontline mastitis control. Academic institutions and government labs continue to drive basic research that filters into commercial solutions, reinforcing an innovation pipeline vital for the bovine mastitis industry.

Geography Analysis

North America generated 33.12% of bovine mastitis market revenue in 2025 and will climb at 4.65% CAGR through 2031. Investment exceeding USD 8 billion in new U.S. processing capacity boosts milk-quality demands, motivating farms to adopt selective therapy and inline diagnostics. The FDA’s evolving antibacterial guidance shapes label claims and withdrawal times, rewarding firms that navigate compliance swiftly.

Europe follows a 4.92% CAGR backed by some of the world’s strictest antimicrobial policies. Regulation 2019/6 pushes selective dry-cow therapy and caps prophylactic use, intensifying demand for sensor-driven treatment decisions and alternative biologics. Nordic producers showcase low somatic-cell averages, proving preventive systems can maintain output while shrinking antibiotic loads.

Asia-Pacific is the fastest propeller with a 5.86% CAGR thanks to surging dairy consumption in China, India, and Southeast Asia. Larger herd sizes, international joint ventures, and Western farming models necessitate structured mastitis control. Investments in milk-analysis labs and vet services unlock pent-up demand for culture kits, vaccines, and AI platforms, enlarging regional share of the bovine mastitis market. Latin America and the Middle East & Africa trail at slightly lower yet robust CAGRs of 5.72% and 5.31% respectively as integrated farm projects scale up in Brazil and the Gulf states.

Regulatory Landscape

The regulatory environment for bovine mastitis products is tightening around antimicrobial stewardship and residue control, which is shaping labels and on-farm protocols. In the United States, FDA CVM published a draft revised Guidance for Industry (GFI) #49 in December 2024 for evaluating target animal safety and effectiveness of antibacterial new animal drugs for bovine mastitis, updating the legacy 1996 framework and reinforcing evidence expectations for antibacterial claims.

In Europe, the Veterinary Medicines Regulation (EU) 2019/6 (applicable since 2022) operationalizes One Health-driven constraints on prophylaxis and raises compliance requirements through antimicrobial-use data reporting (with the first Agency report due by March 31, 2025, and subsequent reporting thereafter). Portfolio risk is also shaped by secondary legislation, including Commission Implementing Regulation (EU) 2024/1973, which enters into effect on August 8, 2026 and restricts or prohibits certain antimicrobials, and Commission Delegated Regulation (EU) 2026/1073 (published March 2026), which amends rules for use of specific veterinary medicinal products for listed diseases. Together, these measures are pushing suppliers toward selective dry-cow therapy and alternatives that reduce reliance on restricted antibiotic classes.

Value Chain Analysis

The bovine mastitis value chain runs from upstream API and excipient sourcing through formulation and fill-finish (intramammary tubes, injectables, and vaccines), then through regulatory release, wholesaler and veterinary channels, and finally into farm-level protocols implemented by dairy farms and cooperatives (the dominant end users in this report scope). Manufacturing for specialized biologics and vaccines is concentrated in facilities in Europe and North America, while many small-molecule APIs are globally sourced, commonly from India and China. As a result, continuity of supply and quality assurance are central to commercial execution.

Downstream, farm adoption is shaped by milk-quality thresholds and standard-setting bodies that influence purchasing toward prevention-centric bundles. The National Mastitis Council maintains a Recommended Mastitis Control Program (seven-point protocol) that supports consistent demand for teat sealants, dry-cow therapy products, and supportive treatments. Public programs such as India's Livestock Health and Disease Control Programme (LH&CP) support mastitis prevention activities, including field distribution of CMT kits via ASCAD, strengthening last-mile implementation. Product innovation also feeds back into the chain: Boehringer Ingelheim's April 2026 launch of LENZELTA in multiple EU countries adds a prevention node that increases requirements for cold-chain handling, veterinarian engagement, and alignment of vaccination scheduling with dry-off management.

Market Opportunities and Future Outlook

Opportunities are expanding where regulators and processors are tightening antimicrobial-use requirements and where farms are shifting from blanket treatment to targeted, prevention-led protocols. In Europe, the transition under Regulation (EU) 2019/6 and related antimicrobial restrictions creates whitespace for solutions that reduce antibiotic exposure while preserving cure outcomes, including vaccines, internal teat sealants used in selective dry-cow therapy programs, and integrated decision tools that support culture-guided treatment at the quarter or cow level.

Commercial and regulatory proof points also support a prevention and precision pivot within the current market. Boehringer Ingelheim launched LENZELTA in April 2026 across several EU countries for S. aureus and E. coli mastitis prevention during the dry-off period. In the same month, Laboratorios HIPRA received a positive CVMP opinion to modify the Startvac vaccination scheme to allow administration independent of parturition dates, which can reduce operational friction for herds that struggle to synchronize dosing to calving. On the technology side, validation work reported in 2026 for point-of-care pathogen identification (for Gram-positive mastitis pathogens) reinforces the on-farm testing pathway that enables selective therapy and supports processor-driven responsible-antibiotic sourcing programs highlighted in this report scope.